The purpose of this review is to provide an overview of diagnosis, prognosis and
management of heart failure (HF) with reduced ejection fraction (HFrEF). Specifically, this …

This review article addresses the question of whether biomarker-guided therapy is ready for
clinical implementation in chronic heart failure. The most well-known biomarkers in heart …

Heart failure (HF) represents a significant global health challenge, characterized by high
morbidity and mortality rates, and imposes considerable burdens on healthcare systems and …

Heart failure (HF) has proven to be a major burden on the health system. The continuing
prevalence of the condition and its rising associated costs and care, has amplified the need …

Since natriuretic peptides were successfully integrated into the clinical practice of heart
failure (HF), the possibility of using new biomarkers to advance the management of affected …

Despite the enhanced knowledge of the pathophysiology of heart failure (HF), it still remains
a serious syndrome with substantial morbidity, mortality, and frequent hospitalizations …

Heart failure (HF) represents a significant global health challenge, characterized by a variety
of symptoms resulting from cardiac dysfunction. This dysfunction often leads to systemic and …

Successful treatment of patients with cardiovascular disease (CVD) has markedly improved
through the deployment of new therapies typically evaluated in large randomized controlled …

Heart failure is a growing epidemic, and our understanding of the intricacies of its
pathophysiology continues to evolve. Over the last decade, biomarkers of heart failure have …

In this Decade in Review article, I highlight the top 10 advances in heart failure (HF) over the
past decade, including new pharmacological therapies and expanded indications for …